公开(公告)号：US12187806B2

公开(公告)日：2025-01-07

申请号：US17686666

申请日：2022-03-04

Applicant: Development Center for Biotechnology

Inventor： Chun-Chung Lee ,  Yu-Hsun Lo ,  Chu-Bin Liao ,  Chen-Jei Hong ,  Sih-Yu Chen ,  Yen-Yu Wu ,  Szu-Liang Lai ,  Chih-Yung Hu ,  Wen-Bin Ke ,  Ya-Ting Juan ,  Kao-Jean Huang

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

公开(公告)号：US10689362B2

公开(公告)日：2020-06-23

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: A61K31/44 ,  A61K31/498 ,  A61P35/00 ,  C07D241/40 ,  C07D241/44 ,  C07D401/06 ,  C07D401/12 ,  C07D241/52 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D401/04 ,  C07D413/12 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12 ,  C07D403/12 ,  C07D403/14

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US20210015942A1

公开(公告)日：2021-01-21

申请号：US16244090

申请日：2019-01-09

Applicant: Development Center for Biotechnology

Inventor： Shih-Hsien Chuang ,  Chu-Bin Liao ,  Wei-Ting Sun ,  Chen-Hsien Liang ,  Wun-Huei Lin ,  Chun-Liang Lai ,  Her-Sheng Lin

IPC: A61K47/68 ,  C07K16/32 ,  A61P35/00

Abstract: An immunoconjugate having the Formula Ab-[L1-(A-L2-B)m]n, wherein: (a) Ab is an antibody or a binding fragment thereof; (b) L1 and L2 are each independently a linker, wherein L1 and L2 are the same or different and wherein L1 links to L2; (c) A is a target-protein ligand/binder; (d) B is a ubiquitin ligase ligand/binder, and (e) n and m are independently integers from 1 to 8. The target protein includes kinase, G protein-coupled receptors, transcription factor, phosphatases, and RAS superfamily members.

公开(公告)号：US20180208561A1

公开(公告)日：2018-07-26

申请号：US15326490

申请日：2015-06-15

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Nan-Horng Lin ,  Chu-Bin Liao ,  Shao-Zheng Peng ,  Shih-Chieh Yen ,  Mann-Yan Kuo

IPC: C07D241/44 ,  A61P35/00 ,  A61P3/10 ,  A61P13/12 ,  A61P9/00 ,  A61P19/02 ,  C07D413/12 ,  C07D401/12 ,  C07D413/04

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

公开(公告)号：US12043668B2

公开(公告)日：2024-07-23

申请号：US17413496

申请日：2019-12-13

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Chen-Hsuan Ho ,  Chu-Bin Liao ,  Yu-Kai Chen ,  Chen-Wei Huang ,  Tze-Ping Yang ,  Szu-Liang Lai

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

公开(公告)号：US11407757B2

公开(公告)日：2022-08-09

申请号：US16958721

申请日：2018-12-26

Applicant: Development Center for Biotechnology

Inventor： Shih-Chieh Yen ,  Chu-Bin Liao ,  Hui-Chen Wang ,  Po-Ting Chen ,  Yu-Chih Pan ,  Tsung-Hui Li ,  Bo-Rong Chen ,  Shian-Yi Chiou

IPC: C07D487/04 ,  A61P35/00

Abstract: Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R1, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

公开(公告)号：US20150158854A1

公开(公告)日：2015-06-11

申请号：US14103662

申请日：2013-12-11

Applicant: Development Center For Biotechnology

Inventor： Mann-Yan Kuo ,  Chu-Bin Liao ,  Shao-Zheng Peng ,  Shih-Chieh Yen ,  Nan-Horng Lin

IPC: C07D417/14 ,  C07D403/04 ,  C07D239/94 ,  C07D401/04

CPC classification number: C07D417/14 ,  C07D239/94 ,  C07D401/04 ,  C07D403/04

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.

Abstract translation: 一种用于治疗具有式（I）结构的蛋白激酶相关疾病或病症的化合物，其中G是杂芳基，杂环或炔基; X为N或CH; L 1是-N（R 7） - ， - O - ， - C（S） - ， - C（O） - 或-S-; L2是-N（R8） - 或-O-; R1和R2独立地是氢，卤素，羟基，氨基，氰基，硝基，羧基，C1-C4烷氧基，C1-C4烷氧基C1-C4烷氧基，N，N-（C1-C4二烷基）氨基C1-C4烷氧基，N - （C 1 -C 4烷基）氨基C 1 -C 4烷氧基，C 1 -C 4烷酰基，C 1 -C 4烷酰氧基，N-（C 1 -C 4烷基）氨基，N，N-（C 1 -C 4二烷基）氨基，C 1 -C 4烷酰基氨基 或杂环基，其中C 1 -C 4烷基任选被一个或多个选自氟和氯的取代基取代; R3，R4和R5独立地是氢，氟或氯; R6是C1-C4烷基或芳基，其任选被一个或多个选自卤素，羟基，氨基，氰基，硝基的取代基取代; 或R6和R8形成5-6元环基或杂环基。

公开(公告)号：US10745360B2

公开(公告)日：2020-08-18

申请号：US15326490

申请日：2015-06-15

Applicant: Development Center for Biotechnology ,  DCB-USA LLC

Inventor： Nan-Horng Lin ,  Chu-Bin Liao ,  Shao-Zheng Peng ,  Shih-Chieh Yen ,  Mann-Yan Kuo

IPC: C07D241/44 ,  C07D401/12 ,  A61P35/00 ,  C07D413/04 ,  C07D413/12 ,  A61P9/00 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：US20190308949A1

公开(公告)日：2019-10-10

申请号：US16340685

申请日：2017-10-09

Applicant: Development Center for Biotechnology

Inventor： Shao-Zheng Peng ,  Chu-Bin Liao ,  Hung-Kai Chen ,  Chen-Hsuan Ho ,  Hung-Jyun Huang ,  Shian-Yi Chiou

IPC: C07D401/12 ,  C07D401/14 ,  C07D241/52 ,  C07D413/04 ,  C07D413/14 ,  A61P35/00

Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

公开(公告)号：US09321762B2

公开(公告)日：2016-04-26

申请号：US14103662

申请日：2013-12-11

Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Inventor： Mann-Yan Kuo ,  Chu-Bin Liao ,  Shao-Zheng Peng ,  Shih-Chieh Yen ,  Nan-Horng Lin

IPC: C07D417/14 ,  C07D239/94 ,  C07D401/04 ,  C07D403/04

CPC classification number: C07D417/14 ,  C07D239/94 ,  C07D401/04 ,  C07D403/04

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.

Abstract translation: 一种用于治疗具有式（I）结构的蛋白激酶相关疾病或病症的化合物，其中G是杂芳基，杂环或炔基; X为N或CH; L 1是-N（R 7） - ， - O - ， - C（S） - ， - C（O） - 或-S-; L2是-N（R8） - 或-O-; R1和R2独立地是氢，卤素，羟基，氨基，氰基，硝基，羧基，C1-C4烷氧基，C1-C4烷氧基C1-C4烷氧基，N，N-（C1-C4二烷基）氨基C1-C4烷氧基，N - （C 1 -C 4烷基）氨基C 1 -C 4烷氧基，C 1 -C 4烷酰基，C 1 -C 4烷酰氧基，N-（C 1 -C 4烷基）氨基，N，N-（C 1 -C 4二烷基）氨基，C 1 -C 4烷酰基氨基 或杂环基，其中C 1 -C 4烷基任选被一个或多个选自氟和氯的取代基取代; R3，R4和R5独立地是氢，氟或氯; R6是C1-C4烷基或芳基，其任选被一个或多个选自卤素，羟基，氨基，氰基，硝基的取代基取代; 或R6和R8形成5-6元环基或杂环基。